natgillin/translations-raw huggingface dataset:
A reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of Soliris. 
Nakon početka liječenja lijekom Soliris, opaženo je smanjenje aktivnosti terminalnih komponenti komplementa i povećanje broja trombocita u odnosu na početnu vrijednost.
Double Blind 
Omjer stope
Solvent: water for injections 
Otapalo: voda za injekcije Kako Soliris izgleda i sadržaj pakiranja
Total 
Nakon
In the eculizumab NMOSD clinical development program, the dose of Soliris in adult patients with NMOSD was 900 mg every 7 ± 2 days for 4 weeks, followed by 1200 mg at Week 5 ± 2 days, then 1200 mg every 14 ± 2 days for the study duration. 
NMOSD-om iznosila je 900 mg svakih 7 ± 2 dana tijekom 4 tjedna, nakon toga je slijedila doza od 1200 mg u 5. tjednu ± 2 dana, a zatim su tijekom trajanja ispitivanja primali 1200 mg svakih
Tinnitus, Vertigo 
kongestija nosa, rinoreja
Age at MG Diagnosis (years), 
Dob u vrijeme dijagnoze MG-a (godine), srednja vrijednost (min, maks)
4.7 Effects on ability to drive and use machines 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Soliris ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Children and adolescents Onbrez Breezhaler should not be given to children or adolescents below the age of 18 years. 
Djeca i adolescenti Onbrez Breezhaler se ne smije davati djeci ili adolescentima mlađim od 18 godina.
These may be signs of a condition called bronchospasm. 
To mogu biti znaci stanja koje se naziva bronhospazam.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahtjevi za podnošenje periodičkih izvješća o neškodljivosti za ovaj lijek definirani su u referentnom popisom datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
Onbrez Breezhaler should only be used during pregnancy if the expected benefits outweigh the potential risks. 
Onbrez Breezhaler se može koristiti tijekom trudnoće samo ako je očekivana korist veća od mogućih rizika.
In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder. 
U ovom pakiranju naći ćete inhalator i kapsule (u blisteru) koje sadrže lijek kao prašak inhalata.
Onbrez Breezhaler should be administered at the same time of the day each day. 
Onbrez Breezhaler treba primjenjivati svakog dana u isto vrijeme.
Do not use Onbrez Breezhaler - if you are allergic to indacaterol or any of the other ingredients of this medicine (listed in section 6). 
Nemojte primjenjivati Onbrez Breezhaler - ako ste alergični na indakaterol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
In particular, please tell your doctor if you are using: medicines for breathing problems that are similar to Onbrez Breezhaler (i.e. medicines such as salmeterol and formoterol). 
Posebno Vas molimo da obavijestite svog liječnika ako uzimate: lijekove za probleme s disanjem koji su slični Onbrez Breezhaleru (tj. lijekovi kao što su salmeterol i formoterol).
If signs suggesting allergic reactions (in particular, difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash) occur, Onbrez Breezhaler should be discontinued immediately and alternative therapy instituted. 
Ako znakovi koji se pojave ukazuju na alergijsku reakciju (osobito poteškoće u disanju ili gutanju, oticanje jezika, usana i lica, urtikarija, osip na koži), primjenu Onbrez Breezhaler treba odmah prekinuti i uvesti alternativnu terapiju.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Onbrez Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja lijekom Onbrez Breezhaler uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
COPD is a long-term disease and you should use Onbrez Breezhaler every day and not only when you have breathing problems or other symptoms of COPD. 
KOPB je dugotrajna bolest i trebate primijeniti Onbrez Breezhaler svaki dan, a ne samo kada imate poteškoće s disanjem ili druge simptome KOPB-a.
Please read the following instructions carefully to learn how to use and care for your Onbrez Breezhaler inhaler. 
Molimo Vas da pažljivo pročitate upute u nastavku kako biste naučili primjenjivati i brinuti se o svom Onbrez Breezhaler inhalatoru.
The 24-hour bronchodilator effect of Onbrez Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis). 
Bronhodilatacijski 24-satni učinak Onbrez Breezhalera bio je zadržan od prve doze kroz jednogodišnje razdoblje liječenja bez dokaza gubitka djelotvornosti (tahifilaksija).
Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse. 
odmah se obratite svom liječniku ako Vam se simptomi KOPB-a (nedostatak daha prilikom udisanja, piskanje pri disanju, kašalj) nisu popravili ili ako su se pogoršali.
The mean of the maximum changes in blood glucose were similar between Onbrez Breezhaler and placebo. 
Srednja vrijednost najvećih promjena glukoze u krvi bila je slična za Onbrez Breezhaler i placebo.
As with other inhalation therapy, administration of Onbrez Breezhaler may result in paradoxical bronchospasm that may be life-threatening. 
Kao i kod drugih inhalacijskih terapija, primjena Onbrez Breezhalera može dovesti do paradoksalnog bronhospazma koji može ugroziti život.
You should not use Onbrez Breezhaler unless your doctor tells you so. 
Nemojte koristiti Onbrez Breezhaler osim ako Vam to nije rekao liječnik.
As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Onbrez Breezhaler treatment and those patients who received placebo or treatment with tiotropium. 
Kao što je pokazano u 605 bolesnika s KOPB-om u dvostruko slijepom, placebo kontroliranom ispitivanju faze III u trajanju od 26 tjedana, nije bilo klinički značajne razlike u razvoju aritmičkih događaja praćenih tijekom 24 sata, na početku i do 3 puta tijekom razdoblja liječenja od 26 tjedana, između bolesnika koji bili liječeni preporučenim dozama Onbrez Breezhalera i onih koji su primali placebo ili bili liječeni tiotropijem.
If you have questions about how long to continue your treatment with Onbrez Breezhaler, talk to your doctor or pharmacist. 
Ako imate pitanja o tome koliko dugo trebate provoditi liječenje Onbrez Breezhalerom, obratite se svom liječniku ili ljekarniku.
Onbrez Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo. 
Dokazano je da Onbrez Breezhaler smanjuje plućnu hiperinflaciju, što dovodi do povećanog kapaciteta udisanja tijekom vježbe i u mirovanju, u usporedbi s placebom.
If you use more Onbrez Breezhaler than you should If you have inhaled too much Onbrez Breezhaler or if someone else uses your capsules, tell your doctor immediately or go to the nearest emergency unit. 
Ako ste udahnuli previše Onbrez Breezhalera ili ako je netko drugi koristio Vaše kapsule, morate odmah obavijestiti svog liječniku ili otići u najbližu jedinicu hitne pomoći.
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Onbrez Breezhaler at the recommended doses than on placebo. 
Tijekom ispitivanja, klinički značajne promjene glukoze u krvi u pravilu su bile češće za 1-2% pri primjeni Onbrez Breezhalera u preporučenim dozama nego pri primjeni placeba.
Therefore, long-acting beta2-adrenergic agonists such as Onbrez Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval. 
Stoga, dugodjelujuće beta2adrenergičke agoniste kao što je Onbrez Breezhaler treba oprezno koristiti u bolesnika s poznatim ili suspektnim produljenjem QT intervala ili u onih koji se liječe lijekom koji utječe na QT interval.
At 600 microgram once-daily, the safety profile of Onbrez Breezhaler was overall similar to that of recommended doses. 
Pri dozi od 600 mikrograma jedanput na dan, sigurnosni profil Onbrez Breezhalera u cjelini je bio sličan onom pri preporučenim dozama.
Concomitant administration of other sympathomimetic medicinal products (alone or as part of combination therapy) may potentiate adverse reactions to Onbrez Breezhaler. 
Istodobna primjena drugih simpatomimetičkih lijekova (samih ili u kombiniranom liječenju) može potencirati nuspojave Onbrez Breezhalera.
The capsules must be administered only using the Onbrez Breezhaler inhaler (see section 6.6). 
Kapsule se moraju primjenjivati samo uz pomoć Onbrez Breezhaler inhalatora (vidjeti dio 6.6).
Systemic exposures (AUC) in rats and mice at the no-observed adverse effect levels in these studies were at least 7- and 49-fold higher, respectively, than in humans treated with Onbrez Breezhaler once a day at a dose of 300 microgram. 
Sistemska izloženost (AUC) na razinama na kojima nisu bile zapažene nuspojave u ovim je ispitivanjima u štakora i miševa bila najmanje 7, odnosno 49 puta veća od one u ljudi liječenih Onbrez Breezhalerom jedanput na dan u dozi od 300 mikrograma.
In addition, patients treated with Onbrez Breezhaler required significantly less rescue medication, had more days when no rescue medication was needed compared to placebo and had a significantly improved percentage of days with no daytime symptoms. 
Osim toga, bolesnici liječeni Onbrez Breezhalerom trebali su značajno manje lijekova za hitno ublažavanje simptoma, imali su više dana bez lijekova za hitno ublažavanje simptoma u usporedbi s placebom te su imali značajno povećanje postotka dana bez dnevnih simptoma.
Onbrez Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. 
Onbrez Breezhaler ne treba koristiti zajedno s drugim dugodjelujućim beta2-adrenergičkim agonistima ili lijekovima koji sadrže dugodjelujuće beta2-adrenergičke agoniste.
The European Medicines Agency has waived the obligation to submit the results of studies with Onbrez Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Onbrez Breezhalera u svim podskupinama pedijatrijske populacije s kroničnom opstruktivnom plućnom bolešću (KOPB) (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Onbrez Breezhaler has no or negligible influence on the ability to drive and use machines. 
Onbrez Breezhaler ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Onbrez Breezhaler is a long-acting beta2-adrenergic agonist, which is only indicated for COPD and should not be used in asthma due to the absence of long-term outcome data in asthma. 
Onbrez Breezhaler je dugodjelujući beta2-adrenergički agonist koji je indiciran samo za KOPB i ne treba se koristiti u astmi jer nema podataka o ishodima pri dugotrajnoj primjeni u astmi.
Paediatric population There is no relevant use of Onbrez Breezhaler in the paediatric population (under 18 years). 
Nema relevantne primjene Onbrez Breezhaler u pedijatrijskoj populaciji (mlađih od 18 godina).
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Onbrez Breezhaler at recommended therapeutic doses (see section 5.1). 
Klinički važni učinci produljenja QTc-intervala nisu bili zapaženi u ispitivanjima Onbrez Breezhalera u preporučenim terapijskim dozama (vidjeti dio 5.1).
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Onbrez Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists. 
Iako nije bio zapažen klinički značajan učinak na kardiovaskularni sustav nakon primjene Onbrez Breezhalera u preporučenim dozama, indakaterol treba, kao i druge beta2-adrenergičke agoniste, oprezno primjenjivati u bolesnika s kardiovaskularnim poremećajima (koronarna srčana bolest, akutni infarkt miokarda, srčane aritmije, hipertenzija), u bolesnika s konvulzivnim poremećajima ili tireotoksikozom te u bolesnika koji imaju neuobičajeni odgovor na beta2-adrenergičke agoniste.
Onbrez Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators. 
Onbrez Breezhaler sadrži djelatnu tvar indakaterol koja pripada skupini lijekova koji se nazivaju bronhodilatatori.
At the recommended doses, the adverse reaction profile of Onbrez Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation. 
U preporučenim dozama profil nuspojava Onbrez Breezhalera u bolesnika s KOPB-om pokazuje klinički beznačajne sistemske učinke beta2-adrenergičke stimulacije.
If paradoxical bronchospasm occurs Onbrez Breezhaler should be discontinued immediately and alternative therapy substituted. 
Ako dođe do pojave paradoksalnog bronhospazma, primjenu Onbrez Breezhalera treba odmah prekinuti i zamijeniti ga drugim lijekom.
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Onbrez Breezhaler inhaler. 
Preporučena doza je udisanje sadržaja jedne kapsule od 150 mikrograma jedanput na dan uz pomoć Onbrez Breezhaler inhalatora.
Onbrez Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies. 
Onbrez Breezhaler primijenjen jedanput na dan u dozi od 150 i 300 mikrograma dosljedno je pružao klinički značajna poboljšanja plućne funkcije (mjereno forsiranim izdisajnim volumenom u jednoj sekundi, FEV1) tijekom 24 sata kroz brojna farmakodinamička ispitivanja i ispitivanja djelotvornosti.
What Onbrez Breezhaler is and what it is used for What you need to know before you use Onbrez Breezhaler How to use Onbrez Breezhaler Possible side effects 
Što je Onbrez Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Onbrez Breezhaler Kako primjenjivati Onbrez Breezhaler Moguće nuspojave
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Onbrez Breezhaler. 
Iako indakaterol nije u pravilu utjecao na reproduktivne parametre u ispitivanju plodnosti u štakora, zapažen je pad broja trudnih F1 potomaka u ispitivanju peri- i post-razvoja u štakora pri izloženosti 14 puta većoj od one u ljudi liječenih Onbrez Breezhalerom.
Immediate hypersensitivity reactions have been reported after administration of Onbrez Breezhaler. 
Reakcije preosjetljivosti su odmah bile prijavljene nakon primjene Onbrez Breezhalera.
Onbrez Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function. 
Onbrez Breezhaler primijenjen jedanput na dan u dozama od 150 mikrograma i 300 mikrograma pokazao je klinički značajna poboljšanja plućne funkcije.
How long to continue your treatment with Onbrez Breezhaler Keep using your treatment with Onbrez Breezhaler for as long as your doctor tells you. 
Koliko dugo trebate nastaviti svoje liječenje Onbrez Breezhalerom Nastavite svoje liječenje Onbrez Breezhalerom toliko dugo koliko Vam je rekao liječnik.
The inhalation of the content of one 300 microgram capsule once a day, using the Onbrez Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD. 
Dokazano je da udisanje sadržaja kapsule od 300 mikrograma jedanput na dan uz pomoć Onbrez Breezhaler inhalatora omogućava dodatnu kliničku korist s obzirom na dispneju, osobito u bolesnika s teškim KOPB-om.
Onbrez Breezhaler has not been investigated in patients with not well controlled diabetes mellitus. 
Onbrez Breezhaler se nije ispitivao u bolesnika s loše kontroliranom šećernom bolešću.
Onbrez Breezhaler capsules must always be stored in the blister, and only removed immediately before use. 
Onbrez Breezhaler kapsule se moraju uvijek čuvati u blisteru te se smiju izvaditi tek neposredno prije primjene.
Your Onbrez Breezhaler pack: Each Onbrez Breezhaler pack contains: one Onbrez Breezhaler inhaler one or more blisters containing Onbrez Breezhaler capsules to be used in the inhaler. 
Vaše Onbrez Breezhaler pakiranje: Jedno Onbrez Breezhaler pakiranje sadrži: jedan Onbrez Breezhaler inhalator jedan ili više blistera koji sadrže Onbrez Breezhaler kapsule koje se koriste u inhalatoru.
Onbrez Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD). 
Onbrez Breezhaler se koristi da bi se olakšalo disanje u odraslih bolesnika koji imaju poteškoće s disanjem zbog plućne bolesti koja se zove kronična opstruktivna plućna bolest (KOPB).
Onbrez Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy. 
Onbrez Breezhaler nije indiciran za liječenje akutnih epizoda bronhospazma, tj. kao lijek za hitna stanja.
There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment. 
Nema podataka o primjeni Onbrez Breezhalera u bolesnika s teškim oštećenjem jetre.
If you forget to inhale a dose, inhale just one dose at the usual time the next day. 
Ako ste zaboravili primijeniti Onbrez Breezhaler Ako ste zaboravili udahnuti svoju dozu, udahnite samo jednu dozu u uobičajeno vrijeme sljedećeg dana.
Only use the capsules with the inhaler provided in this pack (Onbrez Breezhaler inhaler). 
Koristite samo kapsule koje ste dobili uz inhalator u ovom pakiranju (Onbrez Breezhaler inhalator).
Other medicines and Onbrez Breezhaler 
Drugi lijekovi i Onbrez Breezhaler
What Onbrez Breezhaler contains - Each Onbrez Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate. 
Što Onbrez Breezhaler sadrži - Svaka Onbrez Breezhaler 150 mikrogramska kapsula sadrži 150 mikrograma indakaterola u obliku indakaterolmaleata.
The Onbrez Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD. 
Program ispitivanja faze III tijekom razvoja Onbrez Breezhalera uključivao je bolesnike s kliničkom dijagnozom umjerenog do teškog KOPB-a.
Breezhaler capsules with any other inhaler, and do not use Onbrez Breezhaler inhaler to take any other capsule medicine. 
Onbrez Breezhaler kapsule s nekim drugim inhalatorom i ne koristite Onbrez Breezhaler inhalator za primjenu bilo kojeg drugog lijeka u kapsulama.
What Onbrez Breezhaler is and what it is used for 
Što je Onbrez Breezhaler i za što se koristi
Onbrez Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar. 
Onbrez Breezhaler 150 mikrograma kapsule imaju crnu oznaku „IDL 150“ otisnutu iznad crne crte i crni logo proizvođača ( ) otisnut ispod crne crte.
In the event of deterioration of COPD during treatment with Onbrez Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken. 
Ako dođe do pogoršanja KOPB-a tijekom liječenja Onbrez Breezhalerom, bolesnika treba ponovno pregledati i provesti liječenje KOPB-a.
Onbrez Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar. 
Onbrez Breezhaler 300 mikrograma kapsule imaju plavu oznaku „IDL 300“ otisnutu iznad plave crte i plavi logo proizvođača ( ) otisnut ispod plave crte.
The Onbrez Breezhaler inhaler provided with each new prescription should be used. 
Potrebno je koristiti Onbrez Breezhaler inhalator koji se dobije sa svakim novim receptom.
What you need to know before you use Onbrez Breezhaler 
Što morate znati prije nego počnete primjenjivati Onbrez Breezhaler
Talk to your doctor or pharmacist before using Onbrez Breezhaler if you have asthma (in this case you should not use Onbrez Breezhaler). 
Obratite se svom liječniku ili ljekarniku prije nego primijenite Onbrez Breezhaler ako imate astmu (u tom slučaju ne biste trebali koristiti Onbrez Breezhaler). ako imate problema sa srcem. ako imate epilepsiju. ako imate problema sa štitnjačom (tireotoksikoza). ako imate šećernu bolest.
Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. 
Tijekom liječenja Onbrez Breezhalerom, prestanite primjenjivati lijeka i odmah se obratite svom liječniku ako osjetite stezanje grudnog koša, kašljanje, piskanje ili kratkoću daha odmah nakon primjene lijeka.
Upon initiation of treatment with Onbrez Breezhaler plasma glucose should be monitored more closely in diabetic patients. 
Nakon početka liječenja Onbrez Breezhalerom, u bolesnika sa šećernom bolešću treba pomno pratiti glukozu u plazmi.
The Onbrez Breezhaler inhaler enables you to inhale the medicine contained in a capsule. 
Onbrez Breezhaler inhalator Vam omogućava udisati lijek koji se nalazi u kapsuli.
Show the pack of Onbrez Breezhaler. 
Pokažite pakiranje Onbrez Breezhalera.
Always keep the Onbrez Breezhaler inhaler and capsules in a dry place. 
Uvijek držite Onbrez Breezhaler inhalator i kapsule na suhom mjestu.
An increase in the daily dose of Onbrez Breezhaler beyond the maximum dose of 300 microgram is not appropriate. 
Povećanje dnevne doze iznad doze od 300 mikrograma nije primjereno.
- Each Onbrez Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate. 
- Svaka Onbrez Breezhaler 300 mikrogramska kapsula sadrži 300 mikrograma indakaterola u obliku indakaterolmaleata.
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). 
Onbrez Breezhaler je indiciran za terapiju održavanja bronhodilatacije kod opstrukcije dišnih puteva u odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB).
INSTRUCTIONS FOR USE OF ONBREZ BREEZHALER INHALER 
UPUTE ZA PRIMJENU ONBREZ BREEZHALER INHALATORA
The Onbrez Breezhaler inhaler enables you to inhale the medicine contained in an Onbrez Breezhaler capsule. 
Onbrez Breezhaler inhalator Vam omogućuje udisanje lijeka koji se nalazi u Onbrez Breezhaler kapsuli.
When you start a new pack, use the new Onbrez Breezhaler inhaler that is supplied in the pack. 
Kada otvorite novo pakiranje, upotrijebite novi Onbrez Breezhaler inhalator koji je priložen u pakiranju.
Onbrez Breezhaler is a single-dose inhalation device. 
Onbrez Breezhaler je jednodozni inhalator.
Onbrez Breezhaler capsules must not be swallowed. 
Onbrez Breezhaler kapsule se ne smiju progutati.
Carton containing 30 capsules and one Onbrez Breezhaler inhaler. 
Kutija sadrži 30 kapsula i jedan Onbrez Breezhaler inhalator.